OUR THERAPEUTIC AREAS
To discover new treatments that improve patients’ lives, Servier invests close to 20% of its sales revenue (excl. generic medicines) in R&D. The Group focuses its research and development efforts in therapeutic areas where needs are substantial.
ONCOLOGY
With the increase in cancer cases worldwide (+77% by 2050)1, oncology represents one of our priority development areas. Close to 70% of our R&D budget is dedicated to it. We are an innovative player in the treatment of rare cancers, including certain digestive, brain, and hematological cancers.
This approach offers solutions where few players are investing. We aim to provide therapies that aim to change patients’ lives.
Servier conducts its oncology R&D programs around two promising pathways: immuno-oncology and targeted therapies. The first involves stimulating the patient’s immune system against cancer cells, for example through antibodies (monoclonal or bi-/tri-specific), which trigger a targeted response from the body against an aggression, with the aim of protecting it. We have strengthened our research ecosystem in this field with Symphogen, our center of excellence specializing in monoclonal antibodies in Denmark. The second, targeted therapies, allows for the specific targeting of abnormal cells and offers solutions tailored to patients’ needs, particularly for rare cancers where therapeutic solutions are still too few.
- https://www.who.int/fr/news/item/01-02-2024-global-cancer-burden-growing–amidst-mounting-need-for-services
- IQVIA, Analytics Link World 75 countries – MAT Q1-2024
- https://www.who.int/fr/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- https://www.who.int/news-room/fact-sheets/detail/diabetes
CARDIOMETABOLISM
Cardiovascular diseases are the leading cause of mortality in the world3. Committed for 70 years to the treatment of these pathologies, Servier has acquired renowned expertise. Servier has also been committed for many years to fighting diabetes, a complex and progressive disease that affects 830million people worldwide4.
At present, we are pursuing the clinical development of molecular entities in heart failure, stroke, and venous disease complications. In addition, we have partnered with Amgen on the final stage of clinical development of omecamtiv mecarbil, an innovative and promising chronic heart failure treatment. Innovative research programs for the treatment of heart failure in all its forms are underway.
In addition, Wehealth by Servier our eHealth department looks forward to providing patients with innovative eHealth solutions for better care, such as Cardioskin, an intelligent piece of clothing which detects heart rhythm disorders.
NEUROLOGY
Over the past 30 years5, the number of people affected by neurological conditions worldwide has risen considerably. More recent data indicates that more than 3 billion people worldwide6, which is to say over 30% of the global population, are affected by a neurological condition, making these conditions the leading cause of disease and disability. Despite the growing medical need, only a limited number of treatments are available to alter the progression of these disorders or alleviate symptoms.
We are determined to meet this medical need by specifically targeting three families of neurological diseases: refractory epilepsies, rare movement disorders, and neuromuscular disorders.
Our scientific focus targets a limited number of mechanisms of action common to these pathologies, enabling us to develop meaningful strategies to, depending on the disease, slow down or stop their progression, or even prevent the manifestation of symptoms. Our neurology research is focused on antisense oligonucleotides (ASO), small pharmacological molecules, and monoclonal antibodies.
